Ivonescimab

Name: Ivonescimab in EGFR-mutated non-small-cell lung cancer: Clinical presentation - signs and symptoms
Published: 2026-09-14T15:39:06-04:00

EGFR-mutated non-small-cell lung cancer

Manufacturer: Summit Therapeutics
Regulatory submission: BLA submitted in the fourth quarter of 2025
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description

Clinical presentation - signs and symptoms

2 evidence topics · 1 source

Respiratory and thoracic symptoms

“Chest pain” (opens the source at this quote in a new tab)
“Cough that does not go away” (opens the source at this quote in a new tab)
“Coughing up blood” (opens the source at this quote in a new tab)
“Shortness of breath” (opens the source at this quote in a new tab)
“Wheezing” (opens the source at this quote in a new tab)

Constitutional symptoms

“Fatigue” (opens the source at this quote in a new tab)
“Loss of appetite” (opens the source at this quote in a new tab)
“Losing weight without trying” (opens the source at this quote in a new tab)